Bicara Therapeutics(NASDAQ) BCAX

Market Cap$1.61B

Since IPO (2024)+4%

5 YearN/A

1 Year+114%

1 Month-10%

$24.95

+2.76%

+0.67Today

After hours$24.96+$0.01 (+0.04%)

Bicara Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 24.94	2026-08-17

Bicara Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-10.06%	USD 27.73	2026-08-10
1 month	-10.16%	USD 27.76	2026-07-17
3 month	+24.51%	USD 20.03	2026-05-19
Year to date	+48.19%	USD 16.83	2025-12-31
1 year	+114.26%	USD 11.64	2025-08-15
Since inception	+3.72%	USD 23.41	2024-09-13

Bicara Therapeutics Financials at a Glance

Market Cap

$1.61B

Revenue (TTM)

$0.00

Net Income (TTM)

-$185.36M

EPS (TTM)

-$3.09

P/E Ratio

-7.87

Dividend

$0.00

Beta (Volatility)

1.62 (High)

Dividend

$0.00

Beta (Volatility)

1.62 (High)

Price

$24.95

Volume

434,687.135

Open

$24.28

Price

$24.95

Volume

434,687.135

Open

$24.28

Previous Close

$24.94

Daily Range

$24.13 - $25.00

52-Week Range

$10.30 - $30.99

Estimated Earnings Date

Nov 9, 2026

Dividend

$0.00

Beta (Volatility)

1.62 (High)

Price

$24.95

Volume

434,687.135

Open

$24.28

Previous Close

$24.94

Daily Range

$24.13 - $25.00

52-Week Range

$10.30 - $30.99

Estimated Earnings Date

Nov 9, 2026

BCAX News

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?

Robert IzquierdoJun 13, 2026

Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet

Jonathan PoncianoMay 15, 2026

Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000

Sarah SidlowMay 4, 2026

Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?

Robert IzquierdoMar 30, 2026

Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.

Seena HassounaMar 26, 2026

BCAX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bicara Therapeutics

Bicara helps doctors treat cancer by making new medicines for tumors. Their main drug works like a double-sided tool to stop growth. They focus on head and neck cancers that are hard to cure.

A Two-Way Tool Against Cancer

Ficerafusp Alfa: A bifunctional antibody that blocks growth signals and removes immune-suppressing proteins in solid tumors.
Combination Therapies: Treatments using ficerafusp alfa alongside existing medicines like pembrolizumab to help the immune system attack cancer.
Targeted Cancer Programs: Research focused on squamous cell carcinomas, which include specific types of head, neck, skin, and anal cancers.

Deals and Trials

Entered a license agreement with Biocon Limited in October 2019 to develop and sell fusion protein products.
Started a clinical trial partnership with MSD in May 2022 to test drug combinations in human studies.
Launched the FORTIFI-HN01 Phase 2/3 pivotal trial in February 2025 for patients with head and neck cancer.
Initiated a Phase 1/2 proof-of-concept study in 2025 to evaluate treatments for metastatic colorectal cancer.

What Sets Bicara Apart

Bicara uses a dual-targeting approach that helps medicines reach the tumor site while reducing harmful side effects in the rest of the body. The company uses third-party manufacturers to produce its drugs, allowing it to remain flexible without owning expensive factories.

The Financial Picture

Operating income was -$41.1 million in Q4 2025, worsened by 54.4% from Q4 2024.
Net income reached -$37.4 million in Q4 2025, worsened by 78.4% year-over-year.
Operating cash flow was -$23.9 million in Q4 2025, improved by 20.5% from Q4 2024.
Free cash flow reached -$24.1 million in Q4 2025, improved by 19.8% year-over-year.

Bottom Line

Bicara has transitioned from an early-stage startup to a clinical-stage company with a focus on overcoming drug resistance in cancer. Its reliance on dual-action therapies and strategic partnerships defines its current path in the biotechnology sector.

AI Generated • Apr 30, 2026

Industry

Biotechnology

Sector

Health Care

Employees

103

CEO

Claire Mazumdar, PhD, MBA

Website

www.bicara.com

Headquarters

Boston, MA 02116, US

BCAX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-41.49%

Return on Capital

-38.60%

Return on Assets

-36.19%

Earnings Yield

-12.71%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.61B

Shares Outstanding

66.17M

Volume

434.69K

Avg. Volume

722.41K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$201.99M

EBITDA

-$184.38M

Operating Cash Flow

-$134.85M

Capital Expenditure

-$400.00K

Free Cash Flow

-$135.25M

Cash & ST Invst.

$497.26M

Total Debt

$1.16M

Bicara Therapeutics Performance Analysis

Bicara Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Bicara Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	N/A

Bicara Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.70	N/A
2023	2023-12-31	USD -0.96	37.3%
2024	2024-12-31	USD -1.25	30.7%
2025	2025-12-31	USD -2.52	102.0%

Bicara Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-34.0%
Q4	2025-12-31	-1.5%
Q1	2026-03-31	-36.8%
Q2	2026-06-30	11.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.61B

N/A

Market Cap/Employee

$15.60M

N/A

Employees

103

N/A

Net Income

-$55.44M

-102.4%

EBITDA

-$54.71M

-100.3%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$497.26M

+13.9%

Total Debt

$1.16M

-48.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$1.16M

+8.3%

Return on Assets

-36.19%

N/A

Return on Invested Capital

-43.09%

N/A

Free Cash Flow

-$44.27M

-73.0%

Operating Cash Flow

-$44.21M

-72.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MRVIMaravai LifeSciences Holdings, Inc.

MRVIMaravai LifeSciences Holdings, Inc.$5.68-0.35%

FTREFortrea Holdings Inc.

FTREFortrea Holdings Inc.$18.10+3.96%

SEPNSepterna Inc

SEPNSepterna Inc$44.20-0.67%

SVRASavara Inc.

SVRASavara Inc.$5.37-0.19%

KURAKura Oncology, Inc.

KURAKura Oncology, Inc.$11.28+3.87%

PHATPhathom Pharmaceuticals, Inc.

PHATPhathom Pharmaceuticals, Inc.$9.28-3.13%

PRMEPrime Medicine, Inc.

PRMEPrime Medicine, Inc.$3.17+2.59%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.61-0.02%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$146.23+0.04%

IPSTIp Strategy

IPSTIp Strategy$7.39+2.36%

NVDANvidia

NVDANvidia$225.01-0.00%

NOKNokia

NOKNokia$10.78+0.00%

INTCIntel

INTCIntel$103.49+0.01%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$8.69+0.02%

Questions About BCAX

What is the current price of Bicara Therapeutics?

Bicara Therapeutics is trading at $24.94 per share.

What is the 52-week range for Bicara Therapeutics?

Over the past 52 weeks, Bicara Therapeutics has traded between $10.30 and $30.99.

How much debt does Bicara Therapeutics have?

As of the most recent reporting period, Bicara Therapeutics reported total debt of $1.16M.

How much cash does Bicara Therapeutics have on hand?

Bicara Therapeutics reported $96.60M in cash and cash equivalents in its most recent financial results.

What is Bicara Therapeutics’s dividend yield?

Bicara Therapeutics does not currently have a dividend yield.

Bicara Therapeutics(NASDAQ) BCAX

Bicara Therapeutics Financials at a Glance

BCAX News

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?

Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet

Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000

Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?

Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.

BCAX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Bicara Therapeutics

A Two-Way Tool Against Cancer

Deals and Trials

What Sets Bicara Apart

The Financial Picture

Bottom Line

BCAX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Bicara Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BCAX

What is the current price of Bicara Therapeutics?

What is the 52-week range for Bicara Therapeutics?

How much debt does Bicara Therapeutics have?

How much cash does Bicara Therapeutics have on hand?

What is Bicara Therapeutics’s dividend yield?

Premium Investing Services